This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 12496 results found since Jan 2013.
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
Conditions: Analgesia; Abuse Opioids; Pain Interventions: Drug: Buccal Buprenorphine 300 mcg; Drug: Buccal Buprenorphine 600 mcg; Drug: Buccal Buprenorphine 900 mcg; Drug: Buccal Placebo; Drug: Oral Placebo; Drug: Oral immediate-release oxycodone 10mg Sponsors: Vanderbilt University Medical Center; National Institute on Drug Abuse (NIDA) Not yet recruiting
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Collaborative Care Models to Improve Pain and Reduce Opioid Use in Primary Care: a Systematic Review
ConclusionsCCM shows promise for improving pain-related outcomes, as well as facilitating buprenorphine for opioid use disorder. More robust research is needed to determine which aspects of CCM best support improved outcomes and how to maximize the effectiveness of such interventions.
Source: Journal of General Internal Medicine - August 14, 2023 Category: Internal Medicine Source Type: research
Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use Disorder
Conclusions: Patients' initial engagement with treatment for OUD is rarely examined in qualitative research. This study highlights how NPSU amongst patients receiving new forms of such treatment continues to be a challenge. As such, shared decision-making (between providers and patients) regarding treatment goals and NPSU should be central to the delivery of depot buprenorphine treatment programmes.PMID:37571999 | DOI:10.1080/10826084.2023.2244064
Source: Substance Use and Misuse - August 12, 2023 Category: Addiction Authors: Stephen Parkin Joanne Neale John Strang Source Type: research
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
Conditions: Analgesia; Abuse Opioids; Pain Interventions: Drug: Buccal Buprenorphine 300 mcg; Drug: Buccal Buprenorphine 600 mcg; Drug: Buccal Buprenorphine 900 mcg; Drug: Buccal Placebo; Drug: Oral Placebo; Drug: Oral immediate-release oxycodone 10mg Sponsors: Vanderbilt University Medical Center; National Institute on Drug Abuse (NIDA) Not yet recruiting
Source: ClinicalTrials.gov - August 11, 2023 Category: Research Source Type: clinical trials
BUPRENORPHINE AND NALOXONE (buprenorphine hydrochloride and naloxone hydrochloride) tablet PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma
Updated Date: Fri, 11 Aug 2023 00:00:00 EDT
Source: DailyMed Drug Label Updates - August 11, 2023 Category: Drugs & Pharmacology Source Type: alerts
BUPRENORPHINE HCL AND NALOXONE HCL (buprenorphine and naloxone) tablet REMEDYREPACK INC.
Updated Date: Fri, 11 Aug 2023 00:00:00 EDT
Source: DailyMed Drug Label Updates - August 11, 2023 Category: Drugs & Pharmacology Source Type: alerts
Relationship between medication adherence for opioid use disorder and health care costs and health care events in a claims dataset
Medication for opioid use disorder (MOUD) has well-documented benefits for treating OUD, though its efficacy depends on patient adherence. We know little about outcomes of MOUD nonadherence compared to treatment regimens without MOUD, and this article aims to address the gap. This analysis focused on office-based MOUD treatment (buprenorphine and naltrexone) to evaluate the long-term impact of adherence on subsequent health care costs and health care events.
Source: Journal of Substance Abuse Treatment - August 11, 2023 Category: Addiction Authors: Shirley Liao, Steve Jang, Jordan A. Tharp, Natalie A. Lester Source Type: research
Are DEA-waivered buprenorphine prescribers colocated with behavioral health clinicians?
CONCLUSIONS: Optimally distributing the workforce providing MOUD is necessary to broadly ensure the provision of comprehensive MOUD care based on practice guidelines.SCIENTIFIC SIGNIFICANCE: Less than half of all waivered prescribers, outside of hospitals, are colocated with behavioral health clinicians. Findings offer greater clarity on where integrated MOUD is occurring, among which types of providers, and where it needs to be expanded to increase MOUD uptake.PMID:37559344 | DOI:10.1111/ajad.13462
Source: American Journal on Addictions - August 10, 2023 Category: Addiction Authors: Lisa de Saxe Zerden Connor Sullivan Evan Galloway Erica L Richman Maria G Gaiser Brianna Lombardi Source Type: research
